C16H13F6N5O2
Neat
421.30
-20°C
Room Temperature
2088771-61-1; 6EV5E35ZMR; RefChem:1098578; Sitagliptin FP Impurity B; (R)-10-(2, 4, 5-trifluorobenzyl)-3-(trifluoromethyl)-6, 7, 10, 11-tetrahydro-[1, 2, 4]triazolo[3, 4-c][1, 4, 7]triazecine-8, 12(5H, 9H)-dione; (10R)-3-(trifluoromethyl)-10-[(2, 4, 5-trifluorophenyl)methyl]-5, 6, 7, 9, 10, 11-hexahydro-[1, 2, 4]triazolo[3, 4-c][1, 4, 7]triazecine-8, 12-dione; (10R)-6, 7, 10, 11-tetrahydro-3-(trifluoromethyl)-10-[(2, 4, 5-trifluorophenyl)methyl]-1, 2, 4-triazolo[3, 4-c][1, 4, 7]triazecine-8, 12(5H, 9H)-dione; (10R)-6, 7, 10, 11-Tetrahydro-3-(trifluoromethyl)-10-((2, 4, 5-trifluorophenyl)methyl)-1, 2, 4-triazolo(3, 4-C)(1, 4, 7)triazecine-8, 12(5H, 9H)-dione; 1, 2, 4-Triazolo(3, 4-C)(1, 4, 7)triazecine-8, 12(5H, 9H)-dione, 6, 7, 10, 11-tetrahydro-3-(trifluoromethyl)-10-((2, 4, 5-trifluorophenyl)methyl)-, (10R)-; 10-(2, 4, 5-Trifluoro benzyl)-3-(trifluoromethyl)-6, 7, 10, 11-tetrahydro-(1, 2, 4) triazolo(3, 4-C) (1, 4, 7) triazecine-8, 12(5H, 9H)-dione.; (10R)?- 6, ?7, ?10, ?11-?Tetrahydro-?3-?(trifluoromethyl)?-?10-?[(2, ?4, ?5-?trifluorophenyl)?methyl]?-1, ?2, ?4-?triazolo[3, ?4-?c]?[1, ?4, ?7]?triazecine-?8, ?12(5H, ?9H)?-?dione; Sitagliptin Impurity 29; UNII-6EV5E35ZMR; C16H13F6N5O2; CJUCSNDPMOGZTM-MRVPVSSYSA-N; EX-A3082; ARD193848; (R)-Sitagliptin Tablets EP Impurity FP-B; CS-0165432; (R)-10-(2, 4, 5-trifluorobenzyl)-3-(trifluoromethyl)-6, 7, 10, 11-tetrahydro-[1, 2, 4]triazolo[3, 4-c][1, 4, 7]triazecine-8, 12(5H and 9H)-dione? (Sitagliptin Impurity pound(c)
(10R)-3-(trifluoromethyl)-10-[(2, 4, 5-trifluorophenyl)methyl]-5, 6, 7, 9, 10, 11-hexahydro-[1, 2, 4]triazolo[3, 4-c][1, 4, 7]triazecine-8 and 12-dione
InChI=1S/C16H13F6N5O2/c17-9-6-11(19)10(18)4-7(9)3-8-5-12(28)23-1-2-27-13(14(29)24-8)25-26-15(27)16(20,21)22/h4,6,8H,1-3,5H2,(H,23,28)(H,24,29)/t8-/m1/s1